Novartis neuromuscular drug fails key trial, second major setback in days

Novartis's experimental neuromuscular drug failed a pivotal study, marking the company's second major trial collapse within days. The failure adds pressure on Novartis's pipeline and could impact its near-term growth outlook. The specific drug and indication are not disclosed in the item, and the financial impact remains uncertain.